Skip to main content

RayzeBio, Inc.

RYZBDelisted Feb 26, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001825367

RayzeBio, Inc. was delisted on Feb 26, 2024; its insiders filed their last Form 4 on Feb 28, 2024; 107 institutions reported holding it in 13F filings for Q4 2023, worth $3.40B in total; superinvestors Viking Global Investors and HHLR Advisors (Hillhouse) held it.

13F holders, Q1 2024

Institutional positions in RayzeBio, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

RYZB is no longer listed, and 13F filings after Q4 2023 list far fewer holders. See Q4 2023

Institutional holders
0
−106 vs. Q4 2023
Shares held
0
−54.7M (−100.0%) vs. Q4 2023
Total value
$0
−$3.40B (−100.0%) vs. Q4 2023
New holders
0
0 more added
Sold out
106
0 more reduced

1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q4 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting RYZB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2024: 0 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 0 institutionsQ4 2022: 0 institutionsQ1 2023: 0 institutionsQ2 2023: 0 institutionsQ3 2023: 68 institutionsQ4 2023: 107 institutionsQ1 2024: 0 institutionsQ2 2024: 0 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ1 2024: $0
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $0Q4 2022: $0Q1 2023: $0Q2 2023: $0Q3 2023: $1.20BQ4 2023: $3.40BQ1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding RYZB and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20240$0
Q1 20240$0
Q4 2023107$3.40B
Q3 202368$1.20B
Q2 20230$0
Q1 20230$0
Q4 20220$0
Q3 20220$0
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q1 2024

Shares, value and share of portfolio for each institution holding RayzeBio, Inc.; share changes are against Q4 2023.

Institutions holding RYZB in Q1 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Ameritas Investment Partners, Inc.0$00.00%−2,080−100.0%Sold out
Legal & General Group Plc0$00.00%−1,930−100.0%Sold out
Metropolitan Life Insurance Co0$00.00%−1,181−100.0%Sold out
Tower Research Capital LLC (TRC)0$00.00%−826−100.0%Sold out
Washington Trust Advisors, Inc.0$00.00%−136−100.0%Sold out
EntryPoint Capital, LLC0$00.00%−98−100.0%Sold out
Kellner Capital, LLC––––Not filed